The intestinal microbiota can regulate the incidence and development of MASLD via BA metabolism and FXR/TGR5 signal transduction pathways, providing basic evidence for intestinal flora-targeted treatment of MASLD. This evidence concerns the gene GPBAR1 and metabolic dysfunction-associated steatotic liver disease.